OSTEOPORE LIMITED — Capital/Financing Update 2026

Jan 29, 2026

ASX ANNOUNCEMENT

30 January 2026

Osteopore strengthens footprint in Hong Kong with design partnership and its second Global Centre of Excellence

Highlights

• Osteopore strikes partnership with the Tam Shiu Anatomical Modelling Laboratory (Tam Shiu AML) to establish and strengthen digital design and workflows in models, surgical guides, and cutting jigs.

• Osteopore to setup its second Global Centre of Excellence (GCoE) in Hong Kong (HK), the first GCoE outside of Singapore.

Australian-Singaporean regenerative medicine company Osteopore Limited ( ASX: OSX ; Osteopore or Company ) – a global leader in 3D-printed biomimetic and bioresorbable implants – is delighted to announce the signing of a partnership with the Tam Shiu Anatomical Modelling Laboratory (Tam Shiu AML) based at the University of Hong Kong (HKU), to establish and strengthen digital design and workflows in models, surgical guides, and cutting jigs as well as plans to setup its second Global Centre of Excellence.

Osteopore has been strengthening its core competencies in design and manufacturing, with this collaboration being an important next step in enhancing the Company’s potential engagement opportunities with surgeons and the broader hospital ecosystem.

ASX ANNOUNCEMENT

Osteopore and Tam Shiu AML shall cross-pollinate their experiences and competencies in the digital modelling and design of cutting jigs, fixtures, and other intraoperative use models and guides.

In addition, both Osteopore and Tam Shiu AML will share knowledge and expertise in the digital reconstruction of bone gaps and augmentation sites throughout the body, with a specific focus of turning these designs into implantable custom devices in Hong Kong.

Tam Shiu AML is led by Clinical Associate (Cl. Assoc.) Professor Christian Fang Xinshuo, who is also the Deputy Chief of the Division of Orthopaedic Trauma at HKU. Cl. Assoc. Professor Fang is also an honorary consultant at HKU, and provides clinical service at the Queen Mary Hospital, Gleneagles Hong Kong Hospital, and the Hong Kong University Shenzhen Hospital. His clinical, research and publications area focus on general orthopaedic trauma surgery, osteoporosis, polytrauma, pelvic acetabular fractures and clinical applications of 3D printing.

He has received overseas training in Germany, Switzerland, China, Singapore, the United Kingdom and Australia. He holds the Harry Fang gold medal award from the Hong Kong College of Orthopaedic Surgeons. Dr Fang is heavily engaged in clinical training of younger orthopaedic surgeons and is an active faculty for the AO Foundation (a medically-guided, notfor-profit organization, a global network of surgeons, and the premier education, innovation, and research organization for the surgical treatment of trauma and musculoskeletal disorders)[2] , SICOT (Société Internationale de Chirurgie Orthopédique et de Traumatologie)[ 3] and the Hong Kong college of Orthopaedic Surgeons. He is faculty and organizer of over 40 international courses and educational events.

2 https://www.aofoundation.org

3 https://www.sicot.org

ASX ANNOUNCEMENT

The Tam Shui AML was established in 2018 and now provides service to more than 300 patients each year with complex pathologies requiring specialised 3D digital technology for intervention planning[3] .

Osteopore is working towards setting up its first Asia Pacific (APAC) Global Centre of Excellence (GCoE) in Hong Kong. This newly established APAC GCoE will leverage on the framework and experience from Singapore, with the aim of supporting Osteopore’s commercial launch of customised orthopaedic implants in Hong Kong[6] .

Similar to the first GCoE in Singapore[7] , this GCoE will enable Osteopore to co-develop, test, validate, adopt and scale its customised medical device globally while deepening collaboration with Hong Kong’s clinicians and accelerating adoption.

The GCoE’s strategic location in Hong Kong may also provide benefits such as a gateway to the Greater Bay Area. The potential benefits include regulatory harmonisation initiatives that facilitate cross-border use of medical devices and collaborative innovation across the region’s extensive healthcare infrastructure[8] .

The global 3D-printed orthopaedic implants market is forecasted to reach USD 7.5b, growing at a robust compound annual growth rate (CAGR) of 14.5% from 2026 to 2035, driven by customisation, improved fit and faster production times versus traditional manufacturing[9] .

6 ASX Announcement “OSX strikes agreement for orthopaedic products in Hong Kong” 22 January 2026.

7 ASX Announcement “OSX and SingHealth partner on Global Centre of Excellence”, 14 May 2024

8 https://www.bayarea.gov.hk/gbais/tc/development/medical-co-operation/allowing-designated-healthcare-institutions-in-thegreater-bay-area-to-use-hong-kong-registered-drugs-and-medical-devices/

9 https://www.businessresearchinsights.com/zh/market-reports/3d-printed-orthopedic-implants-market-104621?

ASX ANNOUNCEMENT

Hong Kong’s orthopaedic bone filler and bone implant segment is increasingly integrating advanced 3D printing technologies, positioning the region to capitalise on rapid innovation in patient-specific implants, surgical guides and pre-operative models that enhance precision and clinical outcomes. Local clinical and research facilities are already leveraging 3D digital modelling to support complex orthopaedic interventions and personalised instrument production, reflecting broader adoption of 3D printing in surgical practice[10] .

Commenting on the developments in Hong Kong, CEO Dr Yujing Lim, said:

“The Greater Bay area is a region of significant commercial interest for us. We’re glad to form a partnership with Professor Fang and his team at the University of Hong Kong, to develop core competencies that will eventually support our commercial intent.

“The GCoE initiative established in Singapore in 2024 has empowered us in the area of customised implant design for complex bone reconstruction, and we look forward to bringing that expertise to Hong Kong and potentially, the Greater Bay Area”, said Dr Lim.

ENDS

This announcement has been authorised for release to the ASX by the Board of Osteopore Limited .

For more information, please contact:

Dr Yujing Lim Mark Leong Chief Executive Officer Executive Chairman Osteopore Limited Osteopore Limited E: lim_yujing@osteopore.com E: mark_leong@osteopore.com

10 https://www.ortho.hku.hk/research/3d-printing/

ASX ANNOUNCEMENT

About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific microstructured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Some of the statements appearing in this announcement may be similar to forward-looking statements. You should be aware that such statements are only predictions and are subject to inherent risks and uncertainties. Those risks and uncertainties include factors and risks specific to the industries in which the Company operates and proposes to operate as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets, among other things.

Actual events or results may differ materially from the events or results expressed or implied in any forward-looking statement. No forward-looking statement is a guarantee or representation as to future performance or any other future matters, which will be influenced by several factors and subject to various uncertainties and contingencies, many of which will be outside the Company’s control. The Company does not undertake any obligation to update publicly or release any revisions to these forward-looking statements to reflect events or circumstances after today's date or to reflect the occurrence of unanticipated events.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions or conclusions contained in this announcement. To the maximum extent permitted by law, neither of the Company’s Directors, employees, advisors or agents, nor any other person, accepts any liability for any loss arising from the use of the information contained in this announcement.

You are cautioned not to place undue reliance on any forward-looking statement. The forwardlooking statements in this announcement reflect views held only as at the date of this announcement. This announcement is not an offer, invitation or recommendation to subscribe for or purchase securities by the Company. Nor does this announcement constitute investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. Investors should obtain their own advice before making any investment decision.